The University of Chicago Header Logo

Connection

Mary Eileen Dolan to Gene Expression

This is a "connection" page, showing publications Mary Eileen Dolan has written about Gene Expression.
Connection Strength

1.760
  1. Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet. 2012 Feb; 8(2):e1002525.
    View in: PubMed
    Score: 0.304
  2. Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biol. 2009; 9(3):55-63.
    View in: PubMed
    Score: 0.246
  3. Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. Pharmacogenet Genomics. 2008 Jun; 18(6):545-9.
    View in: PubMed
    Score: 0.236
  4. Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics. 2008 May; 9(5):489-92.
    View in: PubMed
    Score: 0.234
  5. Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet. 2008 Mar; 82(3):631-40.
    View in: PubMed
    Score: 0.232
  6. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Hum Mol Genet. 2013 Oct 01; 22(19):4007-20.
    View in: PubMed
    Score: 0.083
  7. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet. 2012 Apr 01; 21(7):1470-80.
    View in: PubMed
    Score: 0.075
  8. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics. 2009 Jan; 3(2):128-42.
    View in: PubMed
    Score: 0.061
  9. Use of cell lines in the investigation of pharmacogenetic loci. Curr Pharm Des. 2009; 15(32):3782-95.
    View in: PubMed
    Score: 0.061
  10. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood. 2009 Mar 05; 113(10):2145-53.
    View in: PubMed
    Score: 0.061
  11. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007 Sep; 81(3):427-37.
    View in: PubMed
    Score: 0.056
  12. High efficiency electroporation of human umbilical cord blood CD34+ hematopoietic precursor cells. Stem Cells. 2001; 19(6):492-9.
    View in: PubMed
    Score: 0.035
  13. Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208.
    View in: PubMed
    Score: 0.023
  14. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
    View in: PubMed
    Score: 0.018
  15. Comprehensive evaluation of the contribution of X chromosome genes to platinum sensitivity. Mol Cancer Ther. 2011 Mar; 10(3):472-80.
    View in: PubMed
    Score: 0.018
  16. PACdb: a database for cell-based pharmacogenomics. Pharmacogenet Genomics. 2010 Apr; 20(4):269-73.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.